Fennec Pharmaceuticals Inc. Common Stock (FENC)
Stock · NASDAQ · Health Care
$10.01as of 10/16/2026
Price chart
Active signals
FENC Signal Track Record
How signals performed across all stocks →What FENC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +1.9% | 57% | August 27, 2026 |
| Bollinger Band Breakdown | 25 | +3.9% | 64% | September 14, 2026 |
| Bollinger Band Breakout | 24 | +1.1% | 54% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -1.0% | 33% | March 2, 2026 |
| Any 20-session window (baseline) | +0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tamp…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 35
- Website
- fennecpharma.com/
Fundamentals
- 1-day range
- $10.02$10.35
- Market cap
- $378.17M
- P/E (trailing)
- —
- P/E (forward)
- 10.66
- EPS (trailing)
- $-0.12
- Dividend yield
- —
- Beta
- 1.21
- Avg. volume
- 189.8K
How Fennec Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Fennec Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
- LXEOLexeo Therapeutics Inc. Common Stock$2.64▼ 4.35%Market cap $357.27MP/E —$2.56$10.99
- STROSutro Biopharma Inc. Common Stock$10.94▼ 4.54%Market cap $400.18MP/E —$7.15$43.85
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $2.64 | ▼ 4.35% | $2.56$10.99 |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $10.94 | ▼ 4.54% | $7.15$43.85 |
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patientsbenzinga · 9/17/2026
- Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026Yahoo · 9/17/2026
Insider Activity
Insider Actions →- Cioffi Christiana Marie · September 30, 2026 · Grant156
- Sayad Pierre Sargis · September 30, 2026 · Grant168
- Evans Terry L · September 30, 2026 · Grant168
- Hackman Jeffrey S. · September 30, 2026 · Grant1.2K
- Andrade Robert · September 30, 2026 · Grant1.7K
- Brughera Marco Maria · September 15, 2026 · Option Exercise15.5K @ $2.11
- Brughera Marco Maria · September 15, 2026 · Sale15.5K @ $10.29
- Raykov Rosty · September 1, 2026 · Sale10.0K @ $12.11
- Raykov Rosty · August 31, 2026 · Grant2.8K
- Cioffi Christiana Marie · August 31, 2026 · Grant156
- Sayad Pierre Sargis · August 31, 2026 · Sale12.0K @ $12.18
- Sayad Pierre Sargis · August 31, 2026 · Grant168
- Evans Terry L · August 31, 2026 · Grant168
- Hackman Jeffrey S. · August 31, 2026 · Grant1.2K
- Andrade Robert · August 31, 2026 · Grant1.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 16.00M
- Total value held
- $97.94M
- Institutional holders
- 88
- Unknown2.91M
- Unknown2.74M
- Unknown2.48M
- Unknown1.98M
- Unknown1.37M
- Unknown897.1K
- Unknown720.1K
- Unknown371.7K
- Unknown359.1K
- Unknown224.4K
See the full, filterable feed with live charts on the MarketWall dashboard.